Targeted antibody therapy and relevant novel biomarkers for precision medicine for rheumatoid arthritis

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Over the past two decades, the management of rheumatoid arthritis (RA) has progressed remarkably, encompassing the development of new diagnostic tools and efficacious biological agents, such as monoclonal antibodies against inflammatory cytokines and surface markers on immune cells. In addition to the significant efficacy of these biological agents, biomarkers for RA are under consideration for their potential to classify heterogeneous patients into several groups based on clinical and immunological phenotypes for the prediction of clinical course and prognosis and the facilitation of appropriate and precise treatment with the appropriate therapeutic monoclonal antibodies. Biomarkers, particularly those for the prediction and monitoring of the responses to therapeutic monoclonal antibodies for RA, are in demand, with many approaches examined in recent years. In this article, we have summarized the background research on biomarkers and introduced recent topics in the field that enable the possible clinical applications of biomarkers, especially those related to pathogenic cytokines, to guide the treatment of RA.

Original languageEnglish
Pages (from-to)511-517
Number of pages7
JournalInternational Immunology
Volume29
Issue number11
DOIs
Publication statusPublished - 2017 Nov 1

Fingerprint

Precision Medicine
Rheumatoid Arthritis
Biomarkers
Antibodies
Monoclonal Antibodies
Biological Factors
Cytokines
Therapeutics
Phenotype
Research

Keywords

  • Biological agents
  • Biomarker
  • Cytokine
  • Monoclonal antibody
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Immunology

Cite this

Targeted antibody therapy and relevant novel biomarkers for precision medicine for rheumatoid arthritis. / Kaneko, Yuko; Takeuchi, Tsutomu.

In: International Immunology, Vol. 29, No. 11, 01.11.2017, p. 511-517.

Research output: Contribution to journalReview article

@article{e5cbf61e6ddf4d83bb5817fb1533b3ae,
title = "Targeted antibody therapy and relevant novel biomarkers for precision medicine for rheumatoid arthritis",
abstract = "Over the past two decades, the management of rheumatoid arthritis (RA) has progressed remarkably, encompassing the development of new diagnostic tools and efficacious biological agents, such as monoclonal antibodies against inflammatory cytokines and surface markers on immune cells. In addition to the significant efficacy of these biological agents, biomarkers for RA are under consideration for their potential to classify heterogeneous patients into several groups based on clinical and immunological phenotypes for the prediction of clinical course and prognosis and the facilitation of appropriate and precise treatment with the appropriate therapeutic monoclonal antibodies. Biomarkers, particularly those for the prediction and monitoring of the responses to therapeutic monoclonal antibodies for RA, are in demand, with many approaches examined in recent years. In this article, we have summarized the background research on biomarkers and introduced recent topics in the field that enable the possible clinical applications of biomarkers, especially those related to pathogenic cytokines, to guide the treatment of RA.",
keywords = "Biological agents, Biomarker, Cytokine, Monoclonal antibody, Rheumatoid arthritis",
author = "Yuko Kaneko and Tsutomu Takeuchi",
year = "2017",
month = "11",
day = "1",
doi = "10.1093/intimm/dxx055",
language = "English",
volume = "29",
pages = "511--517",
journal = "International Immunology",
issn = "0953-8178",
publisher = "Oxford University Press",
number = "11",

}

TY - JOUR

T1 - Targeted antibody therapy and relevant novel biomarkers for precision medicine for rheumatoid arthritis

AU - Kaneko, Yuko

AU - Takeuchi, Tsutomu

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Over the past two decades, the management of rheumatoid arthritis (RA) has progressed remarkably, encompassing the development of new diagnostic tools and efficacious biological agents, such as monoclonal antibodies against inflammatory cytokines and surface markers on immune cells. In addition to the significant efficacy of these biological agents, biomarkers for RA are under consideration for their potential to classify heterogeneous patients into several groups based on clinical and immunological phenotypes for the prediction of clinical course and prognosis and the facilitation of appropriate and precise treatment with the appropriate therapeutic monoclonal antibodies. Biomarkers, particularly those for the prediction and monitoring of the responses to therapeutic monoclonal antibodies for RA, are in demand, with many approaches examined in recent years. In this article, we have summarized the background research on biomarkers and introduced recent topics in the field that enable the possible clinical applications of biomarkers, especially those related to pathogenic cytokines, to guide the treatment of RA.

AB - Over the past two decades, the management of rheumatoid arthritis (RA) has progressed remarkably, encompassing the development of new diagnostic tools and efficacious biological agents, such as monoclonal antibodies against inflammatory cytokines and surface markers on immune cells. In addition to the significant efficacy of these biological agents, biomarkers for RA are under consideration for their potential to classify heterogeneous patients into several groups based on clinical and immunological phenotypes for the prediction of clinical course and prognosis and the facilitation of appropriate and precise treatment with the appropriate therapeutic monoclonal antibodies. Biomarkers, particularly those for the prediction and monitoring of the responses to therapeutic monoclonal antibodies for RA, are in demand, with many approaches examined in recent years. In this article, we have summarized the background research on biomarkers and introduced recent topics in the field that enable the possible clinical applications of biomarkers, especially those related to pathogenic cytokines, to guide the treatment of RA.

KW - Biological agents

KW - Biomarker

KW - Cytokine

KW - Monoclonal antibody

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=85042561493&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042561493&partnerID=8YFLogxK

U2 - 10.1093/intimm/dxx055

DO - 10.1093/intimm/dxx055

M3 - Review article

VL - 29

SP - 511

EP - 517

JO - International Immunology

JF - International Immunology

SN - 0953-8178

IS - 11

ER -